Alligator Bioscience Ab Is A Clinical Stage Biotechnology Company Based In Lundswedenfocused On Developing Antibody Based Pharmaceuticals For Cancer Treatmentfounded In 2001The Company Specializes In Tumor Directed Immunotherapies That Activate The Immune System To Target Cancer Cellsaiming To Improve Treatment Efficacy While Reducing Side Effects The Company Operates Primarily In The Early Phases Of Drug Developmentwhich Includes Identifying Innovative Modes Of Actionproducing And Optimizing New Drug Candidatesand Conducting Preclinical Efficacy And Safety Evaluationsalligator Also Performs Confirmatory Clinical Studies To Validate The Safety And Effectiveness Of Its Drug Candidates In Cancer Patients Alligator Bioscience S Pipeline Features Several Promising Drug Candidatesincluding Mitazalimabator 1017Alg Apv 527Neo X Primeand Ac101Hlx22 Developed In Collaboration With Shanghai Henlius Biotech Incthe Company Is Listed On The Nasdaq Stockholm And Engages With Approximately 11 500 Shareholdersproviding Regular Updates Through Financial Reports And Webinars
